Tag: Tagrisso

Imfinzi significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable nSCLC

Tagrisso approved in the EU for the adjuvant treatment of lung cancer

AZ’s Tagrisso approved in China in early lung cancer

Tagrisso approved in the US for early-stage EGFR-mutated lung cancer

AZ’s Tagrisso scores priority review from FDA with EGFR-mutated lung cancer

AstraZeneca’s Tagrisso reduced risk of disease recurrence in brain in EGFR-mutated lung cancer

Tagrisso demonstrated unprecedented disease-free survival in lung cancer

Tagrisso Phase III ADAURA trial will be unblinded early after overwhelming efficiency in the adjuvant treatment of the patients with EGFR-mutated lung cancer